Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

AAN 2025

The 77th American Academy of Neurology (AAN) Annual Meeting
05–09 April 2025 | San Diego, CA

AAN 2025

The 77th American Academy of Neurology (AAN) Annual Meeting
05–09 April 2025 | San Diego, CA
Coordination of clinical, imaging, and infusion services to manage anti-amyloid therapy for AD 3:04
Coordination of clinical, imaging, and infusion services to manage anti-amyloid therapy for AD
Jeffrey Gelblum • 8 Apr 2025
Advancing anti-amyloid antibody therapies in AD: future directions and improving access 1:52
Advancing anti-amyloid antibody therapies in AD: future directions and improving access
Jeffrey Gelblum • 8 Apr 2025
Barriers and solutions for initiating anti-amyloid therapies for Alzheimer’s disease 3:22
Barriers and solutions for initiating anti-amyloid therapies for Alzheimer’s disease
Jeffrey Gelblum • 8 Apr 2025
The future of immunotherapeutic approaches for the treatment of neurodegenerative diseases 1:58
The future of immunotherapeutic approaches for the treatment of neurodegenerative diseases
Johanne Kaplan • 7 Apr 2025
Promising vaccine targets for alpha-synucleinopathies 1:41
Promising vaccine targets for alpha-synucleinopathies
Johanne Kaplan • 7 Apr 2025
Exploring a vaccine-based approach to targeting Aβ oligomers in Alzheimer’s disease 3:02
Exploring a vaccine-based approach to targeting Aβ oligomers in Alzheimer’s disease
Johanne Kaplan • 7 Apr 2025
Advancing frontotemporal dementia diagnosis through biomarkers and imaging 1:35
Advancing frontotemporal dementia diagnosis through biomarkers and imaging
Bradford Dickerson • 6 Apr 2025
The next steps in antibody development for AD: targeting tau and biomarkers to predict outcomes 1:20
The next steps in antibody development for AD: targeting tau and biomarkers to predict outcomes
Jack Tsao • 8 Apr 2025
The complexity of vaccine development for neurodegenerative diseases 2:33
The complexity of vaccine development for neurodegenerative diseases
Johanne Kaplan • 7 Apr 2025
The clinical experience with lecanemab therapy in patients with MCI and early-stage AD 3:19
The clinical experience with lecanemab therapy in patients with MCI and early-stage AD
Jack Tsao • 8 Apr 2025
From mutation to meaning: revisiting the PSEN1 Alzheimer’s story 12:08
From mutation to meaning: revisiting the PSEN1 Alzheimer’s story
Alberto Espay • 6 Apr 2025
Real-world outcomes with lecanemab in early Alzheimer’s disease 2:10
Real-world outcomes with lecanemab in early Alzheimer’s disease
Justin Moon • 7 Apr 2025
The future of biomarkers in dementia diagnosis and the role of tau-PET imaging 1:10
The future of biomarkers in dementia diagnosis and the role of tau-PET imaging
Marina Scop Medeiros • 8 Apr 2025
Using AI to improve clinical trial screening in neurology 2:06
Using AI to improve clinical trial screening in neurology
Vijaya B. Kolachalama • 8 Apr 2025
The future of AI in neurology 1:12
The future of AI in neurology
Vijaya B. Kolachalama • 8 Apr 2025
The development of a multi-modal AI framework for differential diagnosis of dementia 1:49
The development of a multi-modal AI framework for differential diagnosis of dementia
Vijaya B. Kolachalama • 8 Apr 2025

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals